| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-12-19 | Uniqure (The Netherlands) | nomination | Rare diseases - Genetic diseases | Nomination | ||
| 2016-12-16 | Ionis Pharmaceuticals (USA - CA) AstraZeneca (UK) | antisense therapeutics against five cancer targets, including IONIS-STAT3Rx and IONIS-KRAS-2.5Rx | advanced lymphomas, undisclosed cancers, cardiovascular diseases, metabolic diseases | R&D |
Cancer - Oncology - Cardiovascular diseases - Metabolic diseases | Exercise of an option agreement |
| 2016-12-16 | FIT Biotech (Finland) Innavirvax (France) | DNA-based HIV-vaccine FIT-06 and VAC-3S | HIV infection | development commercialisation |
Infectious diseases | Development agreement |
| 2016-12-16 | CRISPR Therapeutics (Switzerland - USA - MA) Intellia Therapeutics (USA - MA) Caribou Biosciences (USA - CA) ERS Genomics (Ireland) | intellectual property for CRISPR/Cas9 gene editing technology | collaboration | Technology - Services | Collaboration agreement | |
| 2016-12-16 | Cytosen Therapeutics (USA - TX) University of Central Florida (USA - FL) | licensing | Cancer - Oncology | Licensing agreement | ||
| 2016-12-15 | Celgene (USA - NJ) Evotec (Germany) | neurodegenerative diseases including amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease | R&D |
Neurodegenerative diseases | R&D agreement | |
| 2016-12-15 | Noxxon Pharma (Germany) Merck&Co (USA - NJ) | pembrolizumab and olaptesed pegol (NOX-A12) | metastatic colorectal cancer, metastatic pancreatic cancer | clinical research | Cancer - Oncology | Clinical research agreement |
| 2016-12-15 | Elsalys Biotech (France) Transgene (France) | TG3003, now ELB 041 (anti-CD115 antibody) | product acquisition |
Cancer - Oncology | Product acquisition | |
| 2016-12-15 | Confo Therapeutics (Belgium) | chairman of the board of directors | nomination | Nomination | ||
| 2016-12-15 | apceth (Germany) Bluebird bio (USA - MA) | Lenti-D™ and LentiGlobin™ drug products | childhood cerebral adrenoleukodystrophy (CCALD - X-linked adrenoleukodystrophy cerebral childhood) transfusion-dependent ?-thalassemia. | manufacturing - bioproduction | Technology - Services - Rare diseases - Genetic diseases - Hematological diseases | Production agreement |
| 2016-12-14 | Domain Therapeutics (France) Alkermes (Ireland) | GPCR BioSens-All™ technology | licensing |
CNS diseases | Licensing agreement | |
| 2016-12-13 | BMS (USA - NY) | construction of new premises restructuring |
Restructuring | |||
| 2016-12-13 | Audentes Therapeutics (USA - CA) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2016-12-13 | Kite Pharma (USA - CA) Vitruvian Networks (USA - CA) | software solution to support commercial availability of T-cell therapies | collaboration |
Technology - Services | Collaboration agreement | |
| 2016-12-13 | GSK (UK) | global vaccines R&D center in Rockville | opening of new premises | Infectious diseases | Opening of new premises | |
| 2016-12-13 | Audentes Therapeutics (USA - CA) | member of the board of directors | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2016-12-12 | Polyphor (Switzerland) Taisho Pharmaceutical (Japan) | novel drug candidates based on Polyphor’s proprietary macrocycle platform | R&D, research | undisclosed | Milestone | |
| 2016-12-12 | Ipsen (France) | resignation |
Resignation | |||
| 2016-12-12 | Abivax (France) ExpreS2ion Biotechnologies (Denmark) | ABX544 | Ebola fever | development - licensing - commercialisation | Infectious diseases | Services contract |
| 2016-12-12 | Alexion Pharmaceuticals (USA - CT) | nomination | Rare diseases - Genetic diseases | Nomination |
